STAT

3 hospital CEOs to watch in 2018

Because of the industry’s volatility, in 2017, the CEOs of major hospitals postponed expansion plans and those leading nonprofit chains considered massive mergers. What will the new year bring?

As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here

Health care systems faced a lot of uncertainty in 2017. From the repeal of the individual mandate to potential cuts to federal cash, political issues played a key role.

But it wasn’t all politics: Some hospitals were shuttered by , while others closed due to heavy financial losses. Because of the industry’s volatility, the CEOs of major

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks